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ﬂexneri (55.3%), followed by Shigella sonnei (44.1%); however,
S. sonnei is becoming increasingly prevalent. Among the S. ﬂexneri
isolates, serotypes 2a and X variant (-:7,8, E1037) were the two
most prevalent serotypes, and serologically atypical isolates were
also commonly identiﬁed. Overall, S. sonnei, S. ﬂexneri 2a and
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Shigella isolates, and their prevalence increased from 54.0%
during 2003–2004 to 84.1% during 2011–2013. A change was
observed in the serotype distribution of Shigella in China during
this period, and we propose an ideal strategy to inform the
development of a broadly effective Shigella vaccine candidate.
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p://dx.doi.org/10.1016/j.cmi.2014.10.019The Shigella genus is composed of four species, i.e. Shigella
ﬂexneri, Shigella dysenteriae, Shigella boydii, and Shigella sonnei,
which are the causative agents of shigellosis. Shigella infections
require a low inoculum (as few as ten organisms), and this fa-
cilitates person-to-person transmission [1]. Emerging
multidrug-resistant Shigella isolates with resistance to ﬂuo-
roquinolones and extended-spectrum cephalosporins has
exacerbated the public health impact of shigellosis, leading to
increased morbidity, mortality, and treatment costs [2,3]. It is
estimated that, annually, ~164.7 million cases of shigellosis
occur worldwide, with 125 million cases and 14 000 deaths in
Asia [2,4]. In China, shigellosis is still endemic, and is one of the
top three notiﬁable infectious diseases, with nearly half a million
cases reported each year [5,6]. Thus, shigellosis remains an
important public health threat globally, especially in China.
Because of clinical severity, disease burden, the emergence
of antimicrobial resistance and the global failure to develop
new, effective antimicrobial drugs, greater emphasis should be
placed on prevention, especially vaccine development.
Complicating vaccine development is the fact that there are at
least 50 recognized Shigella serotypes, as well as several pro-
visional subserotypes, and the serotype distribution of Shigella
species differs by geographical region, and ﬂuctuates over time
[7]. Therefore, it is vital to better understand the serotype
distribution of Shigella species at a national level to inform
rational vaccine development. As China further strengthens its
role as an economic powerhouse, it is a good choice for
investigating the serotype distribution of Shigella isolates to
inform vaccine development. However, in recent years, limited
nationwide data in different spatiotemporal contexts available
have made the epidemiological situation unclear, although
scattered data have been reported [3,8]. Therefore, we inves-
tigated the serotype distribution of Shigella species at a national
level in the period 2003–2013.
In China, from 2003 to 2013, a total of 2912 Shigella isolates
were identiﬁed from diarrhoeal patients attending sentinel
hospitals participating in a national pathogen-monitoring sys-
tem, representing different economic levels across China. The
Shigella isolates were identiﬁed by the use of API 20E
biochemical strips (bioMérieux, Marcy l’Etoile, France). Sero-
typing was performed by slide agglutination with a commercial
antiserum kit (Denka Seiken, Tokyo, Japan); untypeable isolates
were characterized with a panel of monoclonal antibodies
against S. ﬂexneri (MASF; Reagensia AB, Stockholm, Sweden).
The most common species identiﬁed was S. ﬂexneri (n = 1610,
55.3%), followed by S. sonnei (n = 1284, 44.1%); these two
species accounted for 99.4% of all recovered Shigella isolates.
S. boydii (n = 13, 0.4%) and S. dysenteriae (n = 5, 0.2%) were
rarely encountered (Table 1). Among the 1610 S. ﬂexneriious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Species and serotype distribution of the Shigella isolates in China during 2003–2013
Species/serotype
No. (%) isolates
Southeast
(n [ 1212)
Northwest
(n [ 780)
North
(n [ 440)
South
(n [ 204)
Central
(n [ 127)
Northeast
(n [ 86)
Southwest
(n [ 63)
Total
(n [ 2912)
S. ﬂexneri 511 (42.2) 536 (68.7) 255 (58.0) 169 (82.8) 52 (40.9) 46 (53.5) 41 (65.1) 1610 (55.3)
1a 48 (4.0) 25 (3.2) 8 (1.8) 43 (21.1) 8 (6.3) 10 (11.6) 2 (3.2) 144 (4.9)
1b 1 (0.1) 37 (4.7) 0 2 (1.0) 1 (0.8) 0 25 (39.7) 66 (2.3)
1c 15 (1.2) 2 (0.3) 0 0 0 3 (3.5) 0 20 (0.7)
2a 221 (18.2) 191 (24.5) 32 (7.3) 29 (14.2) 15 (11.8) 5 (5.8) 7 (11.1) 500 (17.2)
2b 32 (2.6) 37 (4.7) 8 (1.8) 3 (1.5) 9 (7.1) 6 (7.0) 0 95 (3.3)
Serotype 2 variant
(II:3,4,7,8)
34 (2.8) 7 (0.9) 1 (0.2) 4 (2.0) 0 0 0 46 (1.6)
3a 3 (0.2) 5 (0.6) 0 22 (10.8) 0 0 1 (1.6) 31 (1.1)
3b 0 1 (0.1) 0 2 (1.0) 0 0 0 3 (0.1)
4a 1 (0.1) 1 (0.1) 0 0 1 (0.8) 0 0 3 (0.1)
4b 0 0 0 0 0 0 0 0
X variant (-:7,8, E1037) 77 (6.4) 136 (17.4) 181 (41.1) 14 (6.9) 14 (11.0) 11 (12.8) 0 433 (14.9)
4s 14 (1.2) 0 8 (1.8) 5 (2.5) 0 0 0 27 (0.9)
5a 0 0 0 0 0 0 0 0
5b 0 2 (0.3) 0 0 0 0 3 (4.8) 5 (0.2)
6 1 (0.1) 12 (1.5) 1 (0.2) 0 0 0 0 14 (0.5)
X 29 (2.4) 44 (5.6) 10 (2.3) 16 (7.8) 4 (3.1) 5 (5.8) 0 108 (3.7)
Y 14 (1.2) 11 (1.4) 2 (0.5) 7 (3.4) 0 2 (2.3) 0 36 (1.2)
Untypeable 21 (1.7) 25 (3.2) 4 (0.9) 22 (10.8) 0 4 (4.7) 3 (4.8) 79 (2.7)
S. sonnei 691 (57.0) 237 (30.4) 185 (42.0) 35 (17.2) 75 (59.1) 39 (45.3) 22 (34.9) 1284 (44.1)
S. dysenteriae 0 4 (0.5) 0 0 0 1 (1.2) 0 5 (0.2)
S. boydii 10 (0.8) 3 (0.4) 0 0 0 0 0 13 (0.4)
S. sonnei + S. ﬂexneri
2a and X variant
(-:7,8, E1037)
989 (81.6) 564 (72.3) 398 (90.5) 78 (38.2) 104 (81.9) 55 (64.0) 29 (46.0) 2217 (76.1)
CMI Qiu et al. Serotype distribution of Shigella in China 252.e6isolates, serotypes 2a (n = 500, 31.1%) and X variant (-:7,8,
E1037; n = 433, 26.9%) were the two most prevalent serotypes,
followed by serotypes 1a (n = 144, 8.9%), X (-:7,8; n = 108,
6.7%), and 2b (n = 95, 5.9%) (Table 1). S. ﬂexneri X variant (-:7,8,
E1037), a newly identiﬁed serotype, now seems to be widely
prevalent in China [6,9].
Obvious regional variation was observed among the Shigella
species and serotypes. S. sonnei appeared to be more prevalent
in central and south-eastern China, whereas S. ﬂexneri was
more prevalent in southern, north-western, and south-western
regions of China (Table 1). Among the S. ﬂexneri serotypes, the
most common serotypes in south-eastern, north western and
central regions of China were all serotype 2a, whereas in
northern and north-eastern regions, the most common sero-
type was S. ﬂexneri X variant (-:7,8, E1037); the most common
serotypes in southern and south-western regions were 1a and
1b, respectively (Table 1). Moreover, we also observed a clearlyTABLE 2. The prevalence of Shigella sonnei and Shigella ﬂexneri ser
Species/serotype
No. (%) isolates
2003–2004
(n [ 235)
2005–2006
(n [ 421)
2007–
(n [
S. sonnei 41 (17.4) 112 (26.6) 208 (4
S. ﬂexneri 194 (82.6) 309 (73.4) 281 (5
S. sonnei + S. ﬂexneri 235 (100.0) 421 (100.0) 489 (9
S. sonnei + S. ﬂexneri
2a and X variant
(-:7,8, E1037)
127 (54.0) 273 (64.8) 389 (7
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inchanging trend in the prevalence of Shigella isolates over time
(Table 2). Alarmingly, S. sonnei isolates were recovered with a
greater frequency over time, increasing from 17.4% during
2003–2004 to 58.2% during 2011–2013; at the same time, the
frequency of recovery of S. ﬂexneri decreased. Among the
S. ﬂexneri isolates, the prevalence of S. ﬂexneri 2a and S. ﬂexneri
X variant (-:7,8, E1037) seemingly ﬂuctuated over time, but
during 2007–2013 the overall proportion of these two sero-
types remained at ~60% of all S. ﬂexneri isolates (Fig. S1).
S. sonnei, along with S. ﬂexneri 2a and S. ﬂexneri X variant (-:7,8,
E1037), increased in frequency from 54.0% during 2003–2004
to 84.1% during 2011–2013 (Table 2).
Furthermore, it is interesting that we identiﬁed a total of 172
serologically atypical isolates, accounting for 5.9% of all Shigella
isolates (Table 1). These isolates were conﬁrmed by
biochemical tests and serotyping as Shigella species. Among the
atypical isolates, 46 (1.6%) were identiﬁed as S. ﬂexneri serotypeogroups in China over time
2008
492)
2009–2010
(n [ 715)
2011–2013
(n [ 1049)
Total
(n [ 2912)
2.3) 312 (43.6) 611 (58.2) 1284 (44.1)
7.1) 390 (54.5) 436 (41.6) 1610 (55.3)
9.4) 702 (98.2) 1047 (99.8) 2894 (99.4)
9.1) 546 (76.4) 882 (84.1) 2217 (76.1)
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 252.e5–252.e8
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20 (0.7%) were 1c [10]; 79 isolates (2.7%) remained untypeable.
During the 1991–2000 period in China, Wang et al. deter-
mined that the most prevalent species of Shigella was S. ﬂexneri
(86%), followed by S. sonnei (12%); the predominant serotype
among S. ﬂexneri was 2a (80%) [11]. However, our study
showed a signiﬁcant shift in the species and serotype distribu-
tion of Shigella in China during the 2003–2013 period. We
found that S. sonnei accounted for 44.1% of all Shigella isolates,
and increased in frequency over time (ranging from 17.4% to
58.2%), while the prevalence of S. ﬂexneri declined (ranging
from 82.6% to 41.6%). Among the S. ﬂexneri isolates, serotypes
2a and X variant (-:7,8, E1037) were the two most common
serotypes, although their frequencies ﬂuctuated with time.
Consistent with previous studies, S. sonnei was more prevalent
in economically developed regions, whereas S. ﬂexneri remained
prevalent in the less developed regions [3,7]. Notably, we also
observed the emergence and prevalence of several atypical
variants of Shigella in China, accounting for 5.9% of all Shigella
isolates. These alarming trends may be largely attributed to the
recent unprecedented changes in China, resulting from rapid
but unbalanced socio-economic development. Accordingly,
these trends, coupled with the emergence of multidrug resis-
tance, have resulted in a changing disease burden of shigellosis
in China. With the globalization of world trade and human
travel, this new situation in China will also have an impact on
other countries. Existing interventions, such as improved sani-
tation and hygiene, cannot on their own control the spread of
Shigella, although they can reduce the shigellosis burden [7,11].
In this context, innovative strategies, particularly vaccine
development, are likely to have a signiﬁcant impact.
Previous studies demonstrated that protection against
Shigella infections is O-antigen dependent, and some serotype-
based vaccines are under development [12,13]. These have
been conﬁrmed not only providing signiﬁcant protection against
epidemiologically important species but also providing cross-
protection among the S. ﬂexneri serotypes [13]. This ﬁnding
suggests that choosing the most common serotypes for inclu-
sion in a multivalent vaccine could provide coverage for most
Shigella species and serotypes. Livio et al. evaluated the po-
tential for a quadrivalent vaccine including O-antigens from
S. ﬂexneri serotypes 2a, 3a and S. ﬂexneri serotype 6, as well as
S. sonnei, which can provide direct coverage against ~64% of the
Shigella isolates from the Global Enteric Multicenter Study, and
cross-protection against up to 88% of all Shigella isolates. In this
study, we observed a distribution of species and serotypes of
Shigella in China that was different from that of the Global
Enteric Multicenter Study. S. sonnei, S. ﬂexneri 2a and S. ﬂexneri
X variant (-:7,8, E1037) were the most prevalent serotypes in
China, and the overall prevalence of these serotypes accountedClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectfor 76.1% of all Shigella isolates. More importantly, the pro-
portion of these three serotypes increased over time, and
during the 2011–2013 period it increased to 84.1% of all
recovered Shigella isolates (Table 2). S. dysenteriae, S. boydii,
S. ﬂexneri 6 and the untypical S. ﬂexneri isolates were rarely
encountered, accounting for only 3.8% of all Shigella isolates.
Excluding these serotypes from a vaccine should therefore be
acceptable for public health interventions. Therefore, we pro-
pose that an effective Shigella vaccine should include, as a
minimum, a combination of S. sonnei, S. ﬂexneri 2a and S. ﬂexneri
X variant (-:7,8, E1037): these should provide direct coverage
against 76.1% of all Shigella isolates in China. Additionally, cross-
protection by a shared type antigen (type II antigen; S. ﬂexneri
2b and S. ﬂexneri 2 variant) and by shared group antigens (group
antigens 3,4, 7,8, and E1037; S. ﬂexneri 1a, 1b, 1c, 3a, 4a, 4s, 5b,
X, and Y) can increase the overall coverage to up to 96.1% of all
Shigella isolates.
In conclusion, we have demonstrated a change in species and
serotype distribution of Shigella in China, and provided data for
the development of a broadly effective Shigella vaccine
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